vs
HAEMONETICS CORP（HAE）与Rapid7, Inc.（RPD）财务数据对比。点击上方公司名可切换其他公司
HAEMONETICS CORP的季度营收约是Rapid7, Inc.的1.6倍（$339.0M vs $217.4M），HAEMONETICS CORP净利率更高（13.2% vs 1.4%，领先11.8%），Rapid7, Inc.同比增速更快（0.5% vs -2.7%），HAEMONETICS CORP自由现金流更多（$87.2M vs $36.4M），过去两年Rapid7, Inc.的营收复合增速更高（3.0% vs 0.4%）
豪洛捷（Haemonetics）是全球血液与血浆供应及服务提供商，于20世纪70年代由艾伦·（杰克）·莱瑟姆博士在马萨诸塞州内蒂克创立，业务围绕血液相关产品及配套服务展开，为全球医疗领域提供血液管理相关的专业解决方案。
Rapid7是全球领先的网络安全企业，提供漏洞管理、威胁检测与响应、云安全、安全分析等全系列安全解决方案，服务全球科技、医疗、金融、制造等行业的各类规模企业及公共部门客户，助力客户高效识别、应对和缓解网络安全风险。
HAE vs RPD — 直观对比
营收规模更大
HAE
是对方的1.6倍
$217.4M
营收增速更快
RPD
高出3.3%
-2.7%
净利率更高
HAE
高出11.8%
1.4%
自由现金流更多
HAE
多$50.8M
$36.4M
两年增速更快
RPD
近两年复合增速
0.4%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $339.0M | $217.4M |
| 净利润 | $44.7M | $3.1M |
| 毛利率 | 59.7% | 68.9% |
| 营业利润率 | 19.9% | 1.0% |
| 净利率 | 13.2% | 1.4% |
| 营收同比 | -2.7% | 0.5% |
| 净利润同比 | 19.3% | 44.1% |
| 每股收益（稀释后） | $0.95 | $0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HAERPD
| Q4 25 | $339.0M | $217.4M | ||
| Q3 25 | $327.3M | $218.0M | ||
| Q2 25 | $321.4M | $214.2M | ||
| Q1 25 | $330.6M | $210.3M | ||
| Q4 24 | $348.5M | $216.3M | ||
| Q3 24 | $345.5M | $214.7M | ||
| Q2 24 | $336.2M | $208.0M | ||
| Q1 24 | — | $205.1M |
净利润HAERPD
| Q4 25 | $44.7M | $3.1M | ||
| Q3 25 | $38.7M | $9.8M | ||
| Q2 25 | $34.0M | $8.3M | ||
| Q1 25 | $58.0M | $2.1M | ||
| Q4 24 | $37.5M | $2.2M | ||
| Q3 24 | $33.8M | $15.4M | ||
| Q2 24 | $38.4M | $6.5M | ||
| Q1 24 | — | $1.4M |
毛利率HAERPD
| Q4 25 | 59.7% | 68.9% | ||
| Q3 25 | 59.5% | 70.2% | ||
| Q2 25 | 59.8% | 70.6% | ||
| Q1 25 | 58.4% | 71.7% | ||
| Q4 24 | 55.5% | 69.5% | ||
| Q3 24 | 54.2% | 70.6% | ||
| Q2 24 | 52.0% | 70.7% | ||
| Q1 24 | — | 70.3% |
营业利润率HAERPD
| Q4 25 | 19.9% | 1.0% | ||
| Q3 25 | 17.9% | 2.7% | ||
| Q2 25 | 16.8% | 1.6% | ||
| Q1 25 | 21.6% | -0.0% | ||
| Q4 24 | 16.9% | 3.4% | ||
| Q3 24 | 15.0% | 6.0% | ||
| Q2 24 | 11.8% | 2.5% | ||
| Q1 24 | — | 4.7% |
净利率HAERPD
| Q4 25 | 13.2% | 1.4% | ||
| Q3 25 | 11.8% | 4.5% | ||
| Q2 25 | 10.6% | 3.9% | ||
| Q1 25 | 17.5% | 1.0% | ||
| Q4 24 | 10.8% | 1.0% | ||
| Q3 24 | 9.8% | 7.2% | ||
| Q2 24 | 11.4% | 3.1% | ||
| Q1 24 | — | 0.7% |
每股收益（稀释后）HAERPD
| Q4 25 | $0.95 | $0.05 | ||
| Q3 25 | $0.81 | $0.15 | ||
| Q2 25 | $0.70 | $0.13 | ||
| Q1 25 | $1.17 | $0.03 | ||
| Q4 24 | $0.74 | $0.08 | ||
| Q3 24 | $0.66 | $0.21 | ||
| Q2 24 | $0.74 | $0.09 | ||
| Q1 24 | — | $0.02 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $363.4M | $474.7M |
| 总债务越低越好 | $1.2B | — |
| 股东权益账面价值 | $911.5M | $154.7M |
| 总资产 | $2.5B | $1.7B |
| 负债/权益比越低杠杆越低 | 1.34× | — |
8季度趋势，按日历期对齐
现金及短期投资HAERPD
| Q4 25 | $363.4M | $474.7M | ||
| Q3 25 | $296.4M | $407.1M | ||
| Q2 25 | $292.9M | $511.7M | ||
| Q1 25 | $306.8M | $493.5M | ||
| Q4 24 | $320.8M | $521.7M | ||
| Q3 24 | $299.3M | $443.7M | ||
| Q2 24 | $344.4M | $442.6M | ||
| Q1 24 | — | $411.7M |
总债务HAERPD
| Q4 25 | $1.2B | — | ||
| Q3 25 | $1.2B | — | ||
| Q2 25 | $1.2B | — | ||
| Q1 25 | $1.2B | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益HAERPD
| Q4 25 | $911.5M | $154.7M | ||
| Q3 25 | $849.2M | $127.2M | ||
| Q2 25 | $882.3M | $90.4M | ||
| Q1 25 | $820.8M | $52.7M | ||
| Q4 24 | $906.9M | $17.7M | ||
| Q3 24 | $878.9M | $-5.1M | ||
| Q2 24 | $905.4M | $-52.6M | ||
| Q1 24 | — | $-86.4M |
总资产HAERPD
| Q4 25 | $2.5B | $1.7B | ||
| Q3 25 | $2.4B | $1.7B | ||
| Q2 25 | $2.5B | $1.6B | ||
| Q1 25 | $2.5B | $1.6B | ||
| Q4 24 | $2.5B | $1.7B | ||
| Q3 24 | $2.5B | $1.6B | ||
| Q2 24 | $2.5B | $1.5B | ||
| Q1 24 | — | $1.5B |
负债/权益比HAERPD
| Q4 25 | 1.34× | — | ||
| Q3 25 | 1.44× | — | ||
| Q2 25 | 1.39× | — | ||
| Q1 25 | 1.49× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $93.6M | $37.6M |
| 自由现金流经营现金流 - 资本支出 | $87.2M | $36.4M |
| 自由现金流率自由现金流/营收 | 25.7% | 16.8% |
| 资本支出强度资本支出/营收 | 1.9% | 0.5% |
| 现金转化率经营现金流/净利润 | 2.09× | 12.01× |
| 过去12个月自由现金流最近4个季度 | $308.1M | $146.2M |
8季度趋势，按日历期对齐
经营现金流HAERPD
| Q4 25 | $93.6M | $37.6M | ||
| Q3 25 | $111.3M | $39.0M | ||
| Q2 25 | $17.4M | $47.5M | ||
| Q1 25 | $116.6M | $29.8M | ||
| Q4 24 | $43.8M | $63.8M | ||
| Q3 24 | $48.8M | $44.0M | ||
| Q2 24 | $-27.4M | $32.9M | ||
| Q1 24 | — | $31.1M |
自由现金流HAERPD
| Q4 25 | $87.2M | $36.4M | ||
| Q3 25 | $106.3M | $34.8M | ||
| Q2 25 | $13.6M | $46.6M | ||
| Q1 25 | $100.9M | $28.4M | ||
| Q4 24 | $35.2M | $62.6M | ||
| Q3 24 | $39.4M | $42.6M | ||
| Q2 24 | $-33.1M | $32.6M | ||
| Q1 24 | — | $30.4M |
自由现金流率HAERPD
| Q4 25 | 25.7% | 16.8% | ||
| Q3 25 | 32.5% | 16.0% | ||
| Q2 25 | 4.2% | 21.8% | ||
| Q1 25 | 30.5% | 13.5% | ||
| Q4 24 | 10.1% | 28.9% | ||
| Q3 24 | 11.4% | 19.9% | ||
| Q2 24 | -9.8% | 15.7% | ||
| Q1 24 | — | 14.8% |
资本支出强度HAERPD
| Q4 25 | 1.9% | 0.5% | ||
| Q3 25 | 1.5% | 1.9% | ||
| Q2 25 | 1.2% | 0.4% | ||
| Q1 25 | 4.7% | 0.6% | ||
| Q4 24 | 2.5% | 0.5% | ||
| Q3 24 | 2.7% | 0.6% | ||
| Q2 24 | 1.7% | 0.1% | ||
| Q1 24 | — | 0.3% |
现金转化率HAERPD
| Q4 25 | 2.09× | 12.01× | ||
| Q3 25 | 2.88× | 3.97× | ||
| Q2 25 | 0.51× | 5.70× | ||
| Q1 25 | 2.01× | 14.14× | ||
| Q4 24 | 1.17× | 29.36× | ||
| Q3 24 | 1.44× | 2.85× | ||
| Q2 24 | -0.71× | 5.03× | ||
| Q1 24 | — | 22.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HAE
| Hospital | $143.5M | 42% |
| Plasma Productsand Services | $138.9M | 41% |
| Blood Center Productsand Services | $56.6M | 17% |
RPD
| Products | $209.1M | 96% |
| Services | $8.2M | 4% |
